Form 8-K - Current report:
SEC Accession No. 0001193125-22-282578
Filing Date
2022-11-10
Accepted
2022-11-10 16:07:13
Documents
12
Period of Report
2022-11-09
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d744480d8k.htm   iXBRL 8-K 25196
  Complete submission text file 0001193125-22-282578.txt   142798

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA akba-20221109.xsd EX-101.SCH 2843
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20221109_lab.xml EX-101.LAB 17237
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20221109_pre.xml EX-101.PRE 10804
6 EXTRACTED XBRL INSTANCE DOCUMENT d744480d8k_htm.xml XML 3279
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 221377106
SIC: 2834 Pharmaceutical Preparations